Chemistry:Lampalizumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | CFD |
| Clinical data | |
| Routes of administration | Intravitreal |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2068H3214N546O676S13 |
| Molar mass | 46958.39 g·mol−1 |
Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.[1][2]
One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point.[3] The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point.[4]
These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy.[5]
References
- ↑ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107". WHO Drug Information 26 (2). https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/lampalizumab.pdf.
- ↑ "Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration" (in en). http://www.roche.com/investors/updates/inv-update-2017-09-08b.htm.
- ↑ "Statement on Chroma Study" (in en). https://www.roche.com/media/store/statements.htm.
- ↑ "Age-related macular degeneration foils drugmakers". Nature Biotechnology 35 (11): 1000–1001. November 2017. doi:10.1038/nbt1117-1000. PMID 29121027.
 |  |
